¼¼°èÀÇ Ãé¿ÜºÐºñ ±â´ÉºÎÀü Ä¡·á ½ÃÀå : ±âȸ¿Í ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¿¹Ãø(2024-2032³â)
Exocrine Pancreatic Insufficiency Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
»óǰÄÚµå : 1618302
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 101 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,679,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,332,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,499,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Ãé¿ÜºÐºñ ±â´ÉºÎÀü Ä¡·á(EPI) ½ÃÀåÀº 2023³â¿¡ 27¾ï ´Þ·¯¿¡ À̸£·¶À¸¸ç, 2024-2032³âÀÇ CAGR ¼ºÀå·üÀº 5.6%·Î ¿¹ÃøµË´Ï´Ù. ¿µ¾ç¼ÒÀÇ ¼ÒÈ­ Èí¼ö¿¡ Áß¿äÇÑ ÃéÀå È¿¼ÒÀÇ ºÎÁ·À» Ư¡À¸·Î, ÀÇ·á Á¢±Ù¹ý°ú ´ÙÀÌ¾îÆ®¸¦ °áÇÕÇÏ¿© °ü¸®µË´Ï´Ù. ¼öÈ®À» ÃËÁøÇϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Ãֽм³¹®Á¶»ç´Â ¸íÈ®ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ °ËÃâÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ÃéÀå ±â´É Æò°¡¿¡ º¯È­¸¦ °¡Á®¿À°í Á¶±â Áø´ÜÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

ÆíÁß ¿¤¶ó½ºÅ¸Á¦-1Àº ³·Àº °ªÀ¸·Î ÃéÀå ±â´É ±â´ÉºÎÀüÀ» ³ªÅ¸³»´Â Çʼö ¹ÙÀÌ¿À¸¶Ä¿·Î µîÀåÇÏ¿© Áø´Ü Á¤¹Ðµµ¸¦ ³ôÀÌ°í ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. PERT ºÎ¹®ÀÌ ½ÃÀå ¼öÀÍÀ» ¼±µµÇϰí 2023³â¿¡´Â 23¾ï ´Þ·¯¿¡ µµ´ÞÇÕ´Ï´Ù. Áõ»ó ¿ÏÈ­¿¡ µµ¿òÀÌ µË´Ï´Ù Áö¹æ, ´Ü¹éÁú, ź¼öÈ­¹°ÀÇ ÀûÀýÇÑ Èí¼ö¸¦ Çã¿ëÇÔÀ¸·Î½á, PERT´Â ¿µ¾ç ºÒ·®, ºñŸ¹Î °áÇÌ, ÀǵµÇÏÁö ¾ÊÀº üÁß °¨¼Ò µî EPI¿Í °ü·ÃµÈ ÇÕº´ÁõÀ» ¿¹¹æÇϰí ȯÀÚÀÇ »ýȰÀÇ ÁúÀ» ´ëÆø °³¼±ÇÕ´Ï´Ù. ¾àÁ¦ À¯Çü¿¡ °üÇØ¼­´Â ½ÃÀå¿¡´Â PERT¿ëÀ¸·Î ¼³°èµÈ ÁÖ¿äÇÑ ¾àÀÌ ÀÖ¾î, °¢°¢ ¿µ¾ç Èí¼ö¸¦ ÃËÁøÇØ EPI¿¡ °ü·ÃµÈ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¶ÀÚÀûÀÎ Á¦Á¦¸¦ Á¦°øÇÕ´Ï´Ù.

¸®ÆÄ¾ÆÁ¦, ÇÁ·ÎÅ×¾ÆÁ¦, ¾Æ¹Ð¶ó¾ÆÁ¦ µîÀÇ È¿¼Ò¸¦ ÀÌ¿ëÇÑ ÀÌ·¯ÇÑ Ä¡·á´Â ¼ÒÈ­°¡ ÀÌ·ç¾îÁö´Â ¼ÒÀå¿¡¼­ È¿¼Ò°¡ È¿°úÀûÀ¸·Î ¹æÃâµÇµµ·Ï Àå¿ë¼º ÄÚÆÃ Ä¸½¶À» ÀÌ¿ëÇÏ¿© È¿À²À» ÃÖÀûÈ­Çϰí ÀÖ½À´Ï´Ù. Á¦ÇüÀº ´Ù¾çÇÑ º¹¿ë·®À¸·Î »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç °³º° ȯÀÚÀÇ ¿ä±¸¿¡ µû¶ó Ä¡·á¸¦ »ç¿ëÀÚ ÁöÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ±¤¹üÀ§ÇÑ Á¶»ç ÀÌ´Ï¼ÅÆ¼ºê, Á¶»ç¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±Ù°ú °°Àº ÇýÅÃÀ» ´©¸®°í EPI Ä¡·áÀÇ °¡¿ë¼º ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. À̸¦ À§ÇØ Àü¹®ÀûÀÎ ¾à¹°°ú Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î ½ÃÀå È®´ë¿Í ȯÀÚ °á°ú °³¼±À» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Ä¡·á ½ÃÀåÀº ²ÙÁØÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

½ÃÀå ±Ô¸ð
½ÃÀÛ³â 2023³â
¿¹Ãø³â 2024-2032³â
½ÃÀÛ °¡°Ý 27¾ï ´Þ·¯
¿¹»ó °¡°Ý 44¾ï ´Þ·¯
CAGR 5.6%

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Ä¡·áº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¾àÁ¦ À¯Çüº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áõ»óº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Exocrine Pancreatic Insufficiency Treatment Market reached USD 2.7 billion in 2023, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency, characterized by a lack of pancreatic enzymes critical for nutrient digestion and absorption, is managed through a combination of medical and dietary approaches. Treatment strategies for EPI aim to reduce symptoms, boost nutrient absorption, and improve the quality of life for those affected by the condition. Significant advancements in diagnostic techniques for EPI are improving detection and supporting more timely, effective treatments. Latest research has aimed at detecting definite biomarkers, which are transforming pancreatic function assessments and facilitating earlier diagnosis.

Fecal elastase-1 has emerged as an essential biomarker, with low levels indicating pancreatic insufficiency, enhancing diagnostic precision and contributing to market expansion. The market is segmented by treatment type into nutritional management and pancreatic enzyme replacement therapy (PERT), with the PERT segment leading in market revenue, reaching USD 2.3 billion in 2023. PERT aids in restoring the body's ability to digest essential nutrients, alleviating common symptoms such as bloating and steatorrhea. By enabling proper absorption of fats, proteins, and carbohydrates, PERT prevents complications associated with EPI, including malnutrition, vitamin deficiencies, and unintended weight loss, significantly improving patients' quality of life. In terms of drug types, the market includes key medications designed for PERT, each offering unique formulations to enhance nutrient absorption and relieve symptoms associated with EPI.

With enzymes like lipase, protease, and amylase, these therapies are optimized for efficiency, utilizing enteric-coated capsules to ensure enzymes are effectively released in the small intestine where digestion occurs. These formulations are available in various dosages, allowing for treatment customization based on individual patient requirements. North America accounted for a major share of the EPI treatment market in 2023, with an anticipated growth reaching USD 2.4 billion by 2032. The region benefits from advanced healthcare infrastructure, extensive research initiatives, and broad access to PERT, driving growth in EPI treatment availability. Additionally, comprehensive insurance coverage and well-established healthcare systems in North America enhance patient access to specialized medications and care, further supporting market expansion and improved patient outcomes.As advancements in diagnostic methods and therapeutic options continue to evolve, the global EPI treatment market is expected to see steady growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$2.7 Billion
Forecast Value$4.4 Billion
CAGR5.6%

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Symptom, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â